AI-Based Image Analysis Software Profiles Cancer Biomarkers in Real Time
By LabMedica International staff writers Posted on 27 Mar 2023 |
Lung cancer is the most widespread type of cancer worldwide, resulting in approximately 1.76 million fatalities annually. Non-small cell lung cancer (NSCLC) accounts for 85% of all lung cancer diagnoses and is typically identified at advanced stages. Due to the late detection of the disease, statistics show that 10-20% of NSCLC patients succumb within 1-3 months of diagnosis. Improving patient care and making targeted therapeutic decisions necessitates the identification of gene alterations. However, only 28% of cancer patients currently undergo a comprehensive analysis of all nine actionable cancer biomarkers, and up to 64% of lung cancer patients do not receive the best available treatment, primarily due to inadequate testing for biomarkers to determine the mutation's nature. Furthermore, in numerous instances, such as with NGS, sensitivity is significantly lower than expected, and interpretability is poor due to the requirement for highly trained specialists who understand what they are examining.
An innovative AI-based system from Imagene (Tel Aviv, Israel) can detect cancer biomarkers in real-time, potentially expediting the administration of treatment. Imagene's cutting-edge system utilizes a biopsy image, generating a biomarker report ready for diagnosis within minutes, precisely identifying the specific cancer mutation present in the biopsy. Currently, the time between biopsy and the initiation of treatment, during which cancer nature is evaluated, typically lasts for several weeks, frequently extending beyond a month. As this waiting period is too long for many patients, Imagene's technology has the potential to significantly reduce it, resulting in patients receiving diagnoses and treatment recommendations on the same day.
Detecting cancer mutations in patients and locations of diverse types is achievable with the aid of AI since cancer patterns tend to repeat themselves. Imagene combines self-supervised learning and other AI techniques, utilizing unlabeled data to enhance results, as well as proprietary processing of prepared data to analyze images. Imagene is presently collaborating with 28 diverse biomarkers across eight organs, demonstrating that their technology is standardized and yields accurate results, aiding in clinical decision-making. Currently, the technology is undergoing clinical research and will soon be commercialized while adhering to regulatory requirements. Ultimately, the technology is expected to be tissue-agnostic.
Related Links:
Imagene
Latest Pathology News
- Robotic Blood Drawing Device to Revolutionize Sample Collection for Diagnostic Testing
- Use of DICOM Images for Pathology Diagnostics Marks Significant Step towards Standardization
- First of Its Kind Universal Tool to Revolutionize Sample Collection for Diagnostic Tests
- AI-Powered Digital Imaging System to Revolutionize Cancer Diagnosis
- New Mycobacterium Tuberculosis Panel to Support Real-Time Surveillance and Combat Antimicrobial Resistance
- New Method Offers Sustainable Approach to Universal Metabolic Cancer Diagnosis
- Spatial Tissue Analysis Identifies Patterns Associated With Ovarian Cancer Relapse
- Unique Hand-Warming Technology Supports High-Quality Fingertip Blood Sample Collection
- Image-Based AI Shows Promise for Parasite Detection in Digitized Stool Samples
- Deep Learning Powered AI Algorithms Improve Skin Cancer Diagnostic Accuracy
- Microfluidic Device for Cancer Detection Precisely Separates Tumor Entities
- Virtual Skin Biopsy Determines Presence of Cancerous Cells
- AI Detects Viable Tumor Cells for Accurate Bone Cancer Prognoses Post Chemotherapy
- First Ever Technique Identifies Single Cancer Cells in Blood for Targeted Treatments
- Innovative Blood Collection Device Overcomes Common Obstacles Related to Phlebotomy
- Intra-Operative POC Device Distinguishes Between Benign and Malignant Ovarian Cysts within 15 Minutes